(413) Antioxidative HABN Targeting Activated Hepatic Stellate Cells for Anti-Hepatic-Fibrosis Therapy

Liver fibrosis, driven by activated hepatic stellate cells (HSCs), is a progressive and life-threatening disease with limited treatment options. Persistent liver damage induces HSC activation, oxidative stress, and excess extracellular matrix deposition. Targeting CD44-overexpressing activated HSCs and reducing oxidative stress presents a novel therapeutic approach. This study introduces a biocompatible nanomedicine combining hyaluronic acid (HA) and bilirubin (BR) to selectively modulate activated HSCs in liver fibrosis.(Fig. 1A)